S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
NASDAQ:NBSE

NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

$0.43
-0.01 (-2.21%)
(As of 09:30 AM ET)
Today's Range
$0.43
$0.43
50-Day Range
$0.48
$1.07
52-Week Range
$0.42
$5.40
Volume
32,132 shs
Average Volume
239,794 shs
Market Capitalization
$1.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NeuBase Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.35mentions of NeuBase Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.63 out of 5 stars

NBSE stock logo

About NeuBase Therapeutics Stock (NASDAQ:NBSE)

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE Stock Price History

NBSE Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
NeuBase Therapeutics Inc
NeuBase Therapeutics, Inc. (NBSE)
NeuBase Therapeutics Inc (O7P.BE)
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
CMU halts licensing agreement with NeuBase Therapeutics
NeuBase Therapeutics Inc NBSE
NeuBase Therapeutics, Inc. (NBSE.MX)
Massive Insider Trade At NeuBase Therapeutics
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
NeuBase Therapeutics (NASDAQ: NBSE)
NeuBase Therapeutics to Explore Strategic Alternatives
Pittsburgh biotech firm amends stock incentive plan
NeuBase Announces 1-for-20 Reverse Stock Split
See More Headlines
Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/23/2021
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NBSE
Fax
N/A
Employees
37
Year Founded
N/A

Profitability

Net Income
$-4,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.04 per share

Miscellaneous

Free Float
3,211,000
Market Cap
$1.62 million
Optionable
Not Optionable
Beta
0.88
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

NBSE Stock Analysis - Frequently Asked Questions

How have NBSE shares performed in 2024?

NeuBase Therapeutics' stock was trading at $0.7401 at the beginning of the year. Since then, NBSE stock has decreased by 42.6% and is now trading at $0.4251.
View the best growth stocks for 2024 here
.

Are investors shorting NeuBase Therapeutics?

NeuBase Therapeutics saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 80,500 shares, a decrease of 59.7% from the February 29th total of 199,800 shares. Based on an average trading volume of 227,500 shares, the short-interest ratio is presently 0.4 days. Approximately 2.7% of the shares of the company are sold short.
View NeuBase Therapeutics' Short Interest
.

When is NeuBase Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our NBSE earnings forecast
.

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its earnings results on Thursday, December, 23rd. The company reported ($4.20) earnings per share for the quarter, beating analysts' consensus estimates of ($4.60) by $0.40.

When did NeuBase Therapeutics' stock split?

NeuBase Therapeutics shares reverse split before market open on Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV).

Who are NeuBase Therapeutics' major shareholders?

NeuBase Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Corp Symetryx, Dietrich A Stephan, Eric I Richman, Todd P Branning and William Roland Mann.
View institutional ownership trends
.

How do I buy shares of NeuBase Therapeutics?

Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBSE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners